Back to Journals » Hypoxia » Volume 4

The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1α in cancer cells, induces cell death, and reduces tumor xenograft growth

Authors Koivunen P, Fell SM, Lu W, Rabinowitz JD, Kung AL, Schlisio S

Received 14 September 2015

Accepted for publication 11 December 2015

Published 4 March 2016 Volume 2016:4 Pages 15—27


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Jose Lopez-Barneo

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Doerthe Katschinski

Peppi Koivunen,1 Stuart M Fell,2,3 Wenyun Lu,4 Joshua D Rabinowitz,4 Andrew L Kung,5,6 Susanne Schlisio,2,7

 1Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland; 2Ludwig Institute for Cancer Research Ltd, Stockholm, Sweden; 3Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden; 4Department of Chemistry and Integrative Genomics, Princeton University, Princeton, NJ, 5Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 6Department of Pediatrics, Columbia University Medical Center, New York, NY, USA; 7Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Abstract: The cellular response to hypoxia is primarily regulated by the hypoxia-inducible factors (HIFs). HIF-1α is also a major mediator of tumor physiology, and its abundance is correlated with therapeutic resistance in a broad range of cancers. Accumulation of HIF-1α under hypoxia is mainly controlled by the oxygen-sensing HIF prolyl 4-hydroxylases (EGLNs, also known as PHDs). Here, we identified a high level of normoxic HIF-1α protein in various cancer cell lines. EGLNs require oxygen and 2-oxoglutarate for enzymatic activity. We tested the ability of several cell-permeable 2-oxoglutarate analogs to regulate the abundance of HIF-1α protein. We identified 3-oxoglutarate as a potent regulator of HIF-1α in normoxic conditions. In contrast to 2-oxoglutarate, 3-oxoglutarate decreased the abundance of HIF-1α protein in several cancer cell lines in normoxia and diminished HIF-1α levels independent of EGLN enzymatic activity. Furthermore, we observed that 3-oxoglutarate was detrimental to cancer cell survival. We show that esterified 3-oxoglutarate, in combination with the cancer chemotherapeutic drug vincristine, induces apoptosis and inhibits tumor growth in vitro and in vivo. Our data imply that a novel treatment strategy targeting HIF-1α in combination with the use of existing cytotoxic agents could serve as potent, future antitumor chemotherapies.

Keywords: cancer, EGLN, HIF, hypoxia, 3-oxoglutarate, prolyl hydroxylase

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Erythropoietin and the use of a transgenic model of erythropoietin-deficient mice

Pichon A, Jeton F, El Hasnaoui-Saadani R, Hagström L, Launay T, Beaudry M, Marchant D, Quidu P, Macarlupu JL, Favret F, Richalet JP, Voituron N

Hypoxia 2016, 4:29-39

Published Date: 7 April 2016

Apoptosis inducing ability of silver decorated highly reduced graphene oxide nanocomposites in A549 lung cancer

Khan M, Khan M, Al-Marri AH, Al-Warthan A, Alkhathlan HZ, Siddiqui MR, Nayak VL, Kamal A, Adil SF

International Journal of Nanomedicine 2016, 11:873-883

Published Date: 7 March 2016

COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma–COPD overlap syndrome

Kurashima K, Takaku Y, Ohta C, Takayanagi N, Yanagisawa T, Sugita Y

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:479-487

Published Date: 4 March 2016

Fifteen days of 3,200 m simulated hypoxia marginally regulates markers for protein synthesis and degradation in human skeletal muscle

D’Hulst G, Ferri A, Naslain D, Bertrand L, Horman S, Francaux M, Bishop DJ, Deldicque L

Hypoxia 2016, 4:1-14

Published Date: 3 March 2016

Induction of long noncoding RNA MALAT1 in hypoxic mice

Lelli A, Nolan KA, Santambrogio S, Gonçalves AF, Schönenberger MJ, Guinot A, Frew IJ, Marti HH, Hoogewijs D, Wenger RH

Hypoxia 2015, 3:45-52

Published Date: 8 October 2015

Frequently asked questions in hypoxia research

Wenger RH, Kurtcuoglu V, Scholz CC, Marti HH, Hoogewijs D

Hypoxia 2015, 3:35-43

Published Date: 18 September 2015

Complex role of HIF in cancer: the known, the unknown, and the unexpected

Tiburcio PD, Choi H, Huang LE

Hypoxia 2014, 2:59-70

Published Date: 18 June 2014

Ovarian cancer: emerging molecular-targeted therapies

Sourbier C

Biologics: Targets and Therapy 2012, 6:147-154

Published Date: 20 June 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010